ANG Lifesciences India Reports Negative Financial Results for Q1 FY25

ANG Lifesciences India, a microcap pharmaceutical company, recently announced its financial results for the quarter ending March 2024. The company’s stock has been given a ‘Strong Sell’ call by MarketsMOJO.

According to the financial report, ANG Lifesciences has seen a negative performance in the quarter, with a score of -18, which has improved from -25 in the last three months. This indicates that the company’s financial health has slightly improved, but it is still facing challenges.

One of the major concerns for ANG Lifesciences is its rising interest cost, which has grown by 52.99% quarter on quarter. This suggests that the company has increased its borrowings, which could put a strain on its finances.

The company’s net sales for the half-yearly period have also shown a decline of -34.71% year on year, indicating a negative trend in its sales. Similarly, the profit after tax (PAT) for the same period has also decreased by -34.71%, highlighting a negative trend in its profitability.

Another area of concern is the company’s inventory turnover ratio, which has fallen each half year in the last five periods. This suggests that the company’s pace of selling inventory has slowed down, which could impact its cash flow.

Similarly, the debtors turnover ratio has also decreased each half year in the last five periods, indicating a slower pace of settling its debtors. This could lead to a strain on the company’s working capital.

In addition, ANG Lifesciences’ debt-equity ratio is at its highest in the last five half-yearly periods, indicating that the company is relying more on borrowings to fund its operations. This could potentially lead to a liquidity crisis for the company.

Overall, ANG Lifesciences’ financial performance for the quarter ending March 2024 has been negative, with several areas of concern. Investors should carefully consider these factors before making any investment decisions.